Company:  CEMPRA, INC. (CEMP)
Form Type:  10-Q
Filing Date:  4/25/2013 
CIK:  0001461993 
Address:  6320 QUADRANGLE DRIVE
SUITE 100
 
City, State, Zip:  CHAPEL HILL, North Carolina 27517-8149 
Telephone:  919-313-6617 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$9.94  
Change: 
0.02 (0.20%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$330.01M
Description of Business
We are a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. Our goal is to develop antibiotics with broad therapeutic potential and the right spectrum of activity to target pathogenic bacteria in adults and children. Broad therapeutic potential means addressing several disease indications. The right spectrum of activity means that, in addition to having activity against bacteria that have become resistant to many currently available antibiotics, the drug does not cause collateral damage to important bacteria such as intestinal microflora so that unintended side effects do not occur. Our lead product, solithromycin (CEM-101), is in Phase 3 clinical trials.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures about ...
      Item 4. Controls and Procedures
    PART II - OTHER INFORMATION
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO
  EXHIBIT 31.2
    CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO
  EXHIBIT 32.1
    CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
  EXHIBIT 32.2
    CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
BROKERAGE PARTNERS